DIRS.INFO The most relevant business & tech news

☆ We're increasing price targets on 3 of our stocks, including 2 crushing the boarder market
▼ + stars: | 2022-11-08 | by ( Jeff Marks | ) www.cnbc.com time to read: +4 min

Following our price target changes on eight Club holdings last month, we're updating three more Tuesday to reflect their recent quarterly earnings reports and outlooks. It's also worth noting that we have not adjusted our Lilly price target since competitor Biogen (BIIB) reported positive topline results from a study to treat early Alzheimer's. Halliburton (HAL): Club price target increasing to $44 per share from $40 This update comes about two weeks after the oilfield services provider reported a stronger-than-expected third quarter . THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.

☆ BioNTech lifts lower end of vaccine sales target range
▼ + stars: | 2022-11-07 | by ( ) www.reuters.com time to read: +1 min

FRANKFURT, Nov 7 (Reuters) - COVID-19 vaccine maker BioNTech (22UAy.DE) on Monday raised the lower bound of its 2022 COVID-19 vaccine revenue guidance for the full year, citing demand for its adapted shots and higher prices. The German biotech firm, the vaccines partner of U.S. pharma giant Pfizer (PFE.N), said in a statement that it is now targeting 16 to 17 billion euros ($16-$17 billion) in vaccine sales, compared with a previous range of 13-17 billion but down from 19 billion euros reported for last year. Partner Pfizer last week raised its forecast for its 2022 sales of the COVID-19 vaccine by $2 billion to $34 billion. Sales during the July-to-September quarter dropped 43% to 3.46 billion euros while net profit fell 44% to 1.78 billion euros. Sales of the Pfizer/BioNTech COVID vaccine are down from pandemic highs as many countries have neared the end of their primary vaccination campaigns.

☆ What the wave of tech layoffs tell us about the economy
▼ + stars: | 2022-11-07 | by ( Nicole Goodkind | ) edition.cnn.com time to read: +7 min

What’s happening: Tech companies are announcing an alarming number of layoffs and hiring freezes. ▸ Lyft (LYFT) said last Thursday that it will lay off 13% of its employees, or nearly 700 people, as it rethinks staffing amid rising inflation and fears of a looming recession. But other companies won’t be immune to the softening demand from consumers and businesses that tech companies have noted. It doesn’t help that the uncertainty around the platform comes at a bad time for ad revenue-dependent tech companies. More potential supply chain woesThe threat of a US rail strike that could disrupt supply chains is still very real.

☆ Gilead, Kite in process of pausing Twitter advertising
▼ + stars: | 2022-11-07 | by ( ) www.reuters.com time to read: +1 min

Nov 7 (Reuters) - Gilead Sciences Inc (GILD.O) said on Monday the company and its unit Kite were in the "process of pausing advertising" on Twitter, after Elon Musk completed his takeover of the social media company. In a statement to Reuters, Gilead said it was monitoring its advertising spend and waiting to better understand how community standards and content moderation will be handled on Twitter now. Gilead joins a growing list of U.S. companies, including General Motors (GM.N) and General Mills (GIS.N), who have either paused or are in the process of re-evaluating advertising on the social media platform. Last week, the Wall Street Journal reported Oreo maker Mondelez International Inc (MDLZ.O) and U.S. drugmaker Pfizer Inc (PFE.N) had also temporarily halted advertising with Twitter. Reporting by Bhanvi Satija and Raghav Mahobe in Bengaluru; Editing by Krishna Chandra EluriOur Standards: The Thomson Reuters Trust Principles.

☆ Scholz secures agreement allowing expats in China to use BioNTech COVID-19 vaccine
▼ + stars: | 2022-11-04 | by ( Andreas Rinke | ) www.reuters.com time to read: +1 min

BEIJING, Nov 4 (Reuters) - German Chancellor Olaf Scholz announced an agreement on Friday to let expatriates in China use the COVID-19 vaccine from Germany's BioNTech (22UAy.DE) and pressed for Beijing to allow the shot to be made freely available to Chinese citizens. On his first visit to China since becoming chancellor and the first by a G7 leader since the pandemic, Scholz said China and Germany had different approaches to fighting the virus but had a joint responsibility to eliminate it. The two countries "agreed on close cooperation in the fight against the pandemic," Scholz said in a briefing alongside the Chinese premier Li Keqiang. "This also includes an approval of the BioNTech vaccine for expatriates in China. I hope that the circle of eligible persons can soon be widened to a general free ability of the BioNTech vaccine," said Scholz.

☆ Factbox: Twitter 2.0: Musk warns of bankruptcy, flip-flops on blue check mark in chaotic start
▼ + stars: | 2022-11-04 | by ( ) www.reuters.com time to read: +5 min

REUTERS/Dado Ruvic/Illustration/File PhotoNov 18 (Reuters) - Twitter has had a bumpy ride since new owner Elon Musk took charge last month. Twitter has also cut staff by half, while Musk has raised the possibility of the social media platform going bankrupt. read more read more* ROLLS OUT $8 SERVICETwitter on Nov. 5 launches an $8 subscription service that gives the user a verified blue check mark and other features. read more* WARNS OF BANKRUPTCYOn his first mass call with employees, Musk raised the possibility of the social media platform going bankrupt, Bloomberg News reported. read more* RELAUNCH $8 SERVICE ON NOV. 29On Nov. 15, Musk said the sought-after blue check subscription service will be relaunched on Nov. 29, a minor delay from his initial tentative timeline.

☆ What Cramer is watching Friday — Starbucks soars on China hope, jobs growth still strong
▼ + stars: | 2022-11-04 | by ( Jim Cramer | ) www.cnbc.com time to read: +5 min

Club holding Coterra Energy (CTRA): In Q3, nearly 500% year-on-year revenue growth to $2.52 billion. Cowen downgrades, sees acute pressure from worsening macro; management pulled 30% growth target. Warner Bros Discovery (WBD): $2.5 billion in cash, $50 billion in gross debt. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio.

☆ New hope China may soften on Covid boosts our stocks most tied to world's No. 2 economy
▼ + stars: | 2022-11-04 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +7 min

After all, Chinese officials have not announced an official transition away from their very strict Covid policy. Nevertheless, the moves in certain stocks tied to China — including many owned by the Club — show the market is taking the vaccine policy change in stride. The cosmetics giant has a big China business and just a few days ago it cut its sales guidance partly due to China's Covid policy. The price move provided some support for oil stocks in Friday's volatile stock market. It's not immediately clear when expatriates in China could actually start getting a shot of the BioNTech-Pfizer Covid vaccine.

☆ Premarket stocks: Interest rates will keep rising. How high will they go?
▼ + stars: | 2022-11-04 | by ( Nicole Goodkind | ) edition.cnn.com time to read: +8 min

What’s happening: No one can move markets like Federal Reserve Chair Jerome Powell — with just a few words on Wednesday he crushed investors’ hopes of an interest rate pivot and sent stocks plunging. “Our decisions will depend on the totality of incoming data and their implications for the outlook for economic activity and inflation,” Powell said on Wednesday. The United Kingdom will face hard economic times and elevated interest rates well into next year, officials warned this week. That will require more interest rate hikes in the coming months, warned policymakers. Several Twitter employees have already filed a class action lawsuit claiming that the layoffs violate the federal Worker Adjustment and Retraining Notification Act.

☆ Factbox: What are the new BQ.1 and BQ.1.1 coronavirus variants, and why it matters
▼ + stars: | 2022-11-04 | by ( Julie Steenhuysen | ) www.reuters.com time to read: +3 min

The following describes the new coronavirus subvariants and how they may impact people. WHAT ARE BQ.1 AND BQ.1.1? In early July, BA.5 became the dominant subvariant of the coronavirus circulating in the United States, but in October it started giving way to BQ.1 and BQ.1.1. A study of blood from three dozen adults showed the shot increased neutralizing antibodies against the BA.4/BA.5 Omicron subvariants by fourfold compared with the original shot after one month. read moreIt is not yet clear whether that will translate into higher protection against the BQ.1 and BQ.1.1 subvariants, but their close relationship to BA.5 may work in the booster's favor.

☆ Pfizer, BioNTech start COVID-flu combination vaccine study
▼ + stars: | 2022-11-03 | by ( ) www.reuters.com time to read: +1 min

Nov 3 (Reuters) - U.S. drugmaker Pfizer Inc (PFE.N) and its German partner BioNTech SE have started an early-stage study to evaluate a combination vaccine targeting COVID-19 and influenza, the companies said on Thursday. The single-dose vaccine candidate is a combination of Pfizer's mRNA-based flu shot and the companies' Omicron-tailored COVID-19 booster shot. The early-stage study, which is being sponsored by BioNTech, aims to evaluate the combination shot's safety, tolerability and immunogenicity, or the ability to generate immune response. Rivals Moderna Inc (MRNA.O) and Novavax Inc (NVAX.O) are also developing combination vaccines targeting both COVID-19 and influenza. read moreReporting by Bhanvi Satija in Bengaluru; Editing by Savio D'Souza and Vinay DwivediOur Standards: The Thomson Reuters Trust Principles.

☆ Cheerios maker General Mills, Audi of America pause advertising on Twitter
▼ + stars: | 2022-11-03 | by ( ) www.reuters.com time to read: +2 min

[1/2] Packages of Cheerios, a brand owned by General Mills, are seen in a store in Manhattan, New York, U.S., November 12, 2021. REUTERS/Andrew KellyNov 3 (Reuters) - General Mills Inc (GIS.N) and Luxury automaker Audi of America said on Thursday they have paused advertising on Twitter, days after the social media platform was acquired by billionaire Elon Musk for $44 billion. "We will continue to monitor this new direction and evaluate our marketing spend," a General Mills spokesperson said. Audi of America, the Herndon, Virginia-based U.S. unit of Audi - a Volkswagen Group (VOWG_p.DE) brand - said it would "continue to evaluate the situation." The two companies join top U.S. automaker General Motors Co (GM.N), which last week said it had temporarily halted paid advertising on Twitter.

☆ Moderna cuts COVID vaccine sales forecast on supply woes, shares tumble
▼ + stars: | 2022-11-03 | by ( ) www.reuters.com time to read: +1 min

Nov 3 (Reuters) - Moderna Inc (MRNA.O) cut its annual sales forecast for its COVID-19 vaccine on Thursday, citing short-term supply constraints that would push some deliveries out to next year, sending its shares down nearly 16% before the bell. It now expects vaccine sales of $18 billion and $19 billion this year compared to a prior forecast of $21 billion. Some U.S. pharmacies in September had reported that government supply of Moderna's updated shot remains limited, causing appointments for the product to vary across the country. Moderna's forecast cut comes just two days after rival Pfizer Inc's (PFE.N) quarterly sales of its COVID-19 vaccine exceeded market expectations and the drugmaker raised the full-year sales forecast for its shots. The vaccine maker reported sales of $3.36 billion in the third quarter, missing Wall Street estimates of $3.53 billion.

☆ GSK lifts earnings view again after forecast-beating quarter
▼ + stars: | 2022-11-02 | by ( Natalie Grover | ) www.reuters.com time to read: +2 min

[1/2] GSK (GlaxoSmithKline) logo is seen in this illustration, August 10, 2022. Shingrix generated sales of 760 million pounds ($873 million) compared with the GSK-compiled analyst consensus forecast for 685 million pounds. In July, GSK had predicted 2022 sales growth of 6% to 8% and adjusted operating profit to climb by 13% to 15%, both increases on forecasts issued in February. GSK said it had incurred a charge of 45 million pounds in the third quarter, primarily reflecting provisions for increased legal fees related to heartburn drug Zantac. Originally marketed by a forerunner of GSK, Zantac has been sold by several companies at different times, including Pfizer (PFE.N), Boehringer Ingelheim and Sanofi (SASY.PA) as well as a plethora of generic drugmakers.

☆ Swiss drugs regulator looking into bubbles in COVID booster vials
▼ + stars: | 2022-11-02 | by ( ) www.reuters.com time to read: +1 min

BERLIN, Nov 2 (Reuters) - Swiss drugs regulator Swissmedic said on Wednesday it is examining potential risks in connection with bubbles that appeared in vials of COVID-19 vaccine boosters retooled to target the Omicron variant of the coronavirus. "Vials of the batch concerned contained bubbles after being removed from the fridge," said Swissmedic, adding that the phenomenon seems to be accentuated when the syringes were prepared several hours in advance. Cantons and vaccination centres have been informed as a precaution, the regulator said. A BioNTech spokesperson said Pfizer was in charge of the supply chain and distribution in Switzerland and had no further immediate comment. Writing by Miranda Murray; Editing by Thomas Escritt and Bill BerkrotOur Standards: The Thomson Reuters Trust Principles.

☆ New GSK shines brighter with another forecast upgrade
▼ + stars: | 2022-11-02 | by ( Natalie Grover | ) www.reuters.com time to read: +3 min

Shingrix generated quarterly sales of 760 million pounds ($873 million), compared with the GSK-compiled analyst consensus forecast for 685 million pounds. GSK shares hit a 2-1/2 month high of 1,470.2 pence in early trade and were last up 1% at 1,461.3 pence. GSK said it had incurred a charge of 45 million pounds in the third quarter, primarily reflecting provisions for increased legal fees related Zantac. Originally marketed by a forerunner of GSK, Zantac has been sold by companies including Pfizer (PFE.N), Boehringer Ingelheim and Sanofi (SASY.PA), as well as many generic drugmakers. GSK reported a third-quarter adjusted profit of 46.9 pence per share on sales of about 7.83 billion pounds, topping analysts' forecasts for 40.1 pence and 7.32 billion pounds.

☆ Wall St slips as jobs data dents hopes for Fed rate deceleration
▼ + stars: | 2022-11-01 | by ( Chuck Mikolajczak | ) www.reuters.com time to read: +4 min

The sharp focus on labor market data overshadowed another report which showed U.S. manufacturing activity grew at its slowest pace in nearly 2-1/2 years in October as rising rates cool demand for goods and pricing pressures on manufacturers lessened. People are seen on Wall Street outside the New York Stock Exchange (NYSE) in New York City, U.S., March 19, 2021. That also helped boost U.S.-listed shares of Chinese firms such as JD.Com , up 3.08% and Alibaba Group Holding , which gained 3.59%. Advancing issues outnumbered declining ones on the NYSE by a 1.56-to-1 ratio; on Nasdaq, a 1.29-to-1 ratio favored advancers. The S&P 500 posted 24 new 52-week highs and eight new lows; the Nasdaq Composite recorded 120 new highs and 110 new lows.

☆ Wall St slips as jobs data dents Fed deceleration wish
▼ + stars: | 2022-11-01 | by ( Chuck Mikolajczak | ) www.reuters.com time to read: +3 min

Investors have been paying close attention to labor market data for any signs of weakening in the job market, as decreasing wage pressures and easing demand would help reduce inflation, giving the Fed the ammunition to begin decelerating with a 50-basis-point rate hike in December. "From an employment standpoint things look really robust though, and that is putting some pressure on stocks." According to preliminary data, the S&P 500 (.SPX) lost 16.26 points, or 0.42%, to end at 3,855.79 points, while the Nasdaq Composite (.IXIC) lost 97.62 points, or 0.90%, to 10,889.23. Megacap growth names such as Amazon (AMZN.O) and Apple (AAPL.O), which have struggled since the Fed began raising interest rates, were once again under pressure. Pfizer (PFE.N) rose after the drugmaker raised full-year sales estimates for its COVID-19 vaccine, while Eli Lilly (LLY.N) fell after trimming its profit forecast.

Nov 1 (Reuters) - Pfizer Inc (PFE.N) on Tuesday raised its forecast for 2022 sales of its COVID-19 vaccine by $2 billion to $34 billion, and said new deals and drugs in development should help replace future declining vaccine sales and lost revenue from patent expirations. Sales of the Pfizer/BioNTech COVID vaccine are down from pandemic highs as many countries have neared the end of their primary vaccination campaigns. Third-quarter sales of the COVID vaccine came in at $4.40 billion, blowing past estimates of $2.60 billion. However, $7.51 billion in sales of Paxlovid, the company's COVID-19 antiviral treatment, fell short of estimates of $7.66 billion. Pfizer reported adjusted earnings of $1.78 per share in the third quarter, beating analysts' estimates by 39 cents.

☆ Pfizer boosts COVID vaccine sales forecast by $2 bln
▼ + stars: | 2022-11-01 | by ( Manas Mishra | ) www.reuters.com time to read: +2 min

Nov 1 (Reuters) - Pfizer Inc (PFE.N) on Tuesday raised its forecast for annual sales of its COVID-19 vaccine by $2 billion to $34 billion on demand for Omicron-targeted boosters, helping allay some investor worries over growth for the vaccinations. The U.S. drugmaker's shares rose 2.4% to $447.67 in morning trading as its third-quarter profit beat estimates, mainly due to better-than-expected sales of the vaccine. The upbeat earnings also sent shares of rival COVID-19 vaccine makers higher. Sales of the COVID-19 vaccine have eased from pandemic highs on soft demand for the original shots, sparking concerns over demand over the next few years. Third-quarter sales of the COVID-19 vaccine came in at $4.40 billion, blowing past estimates of $2.60 billion.

☆ Pfizer boosts COVID vaccine sales forecast by $2 bln to $34 bln
▼ + stars: | 2022-11-01 | by ( ) www.reuters.com time to read: +2 min

Nov 1 (Reuters) - Pfizer Inc (PFE.N) on Tuesday raised its forecast for annual sales of its COVID-19 vaccine by $2 billion to $34 billion on demand for Omicron-targeted boosters, helping allay some investor worries over growth for the vaccinations. The U.S. drugmaker's shares rose 4.3% to $48.55 in premarket trading as its third-quarter profit beat estimates, mainly due to better-than-expected sales of the vaccine. Sales of the COVID-19 vaccine have eased from pandemic highs on soft demand for the original shots, sparking concerns over demand over the next few years. Third-quarter sales of the COVID-19 vaccine came in at $4.40 billion, blowing past estimates of $2.60 billion, according to five analysts polled by Refinitiv. However, $7.51 billion in sales of the company's COVID-19 pill Paxlovid missed estimates of $7.66 billion.

☆ Pfizer raises sales estimates for COVID vaccine by $2 billion
▼ + stars: | 2022-11-01 | by ( ) www.reuters.com time to read: +2 min

Nov 1 (Reuters) - Pfizer Inc (PFE.N) on Tuesday raised full-year estimates for sales of its COVID-19 vaccine by $2 billion to $34 billion, encouraged by demand for its new Omicron-focused booster shots. The company maintained its full-year sales forecast for COVID-19 pill Paxlovid at $22 billion. The company reported third-quarter sales of $22.60 billion, beating analysts' estimates of $21.04 billion, according to IBES data from Refinitiv. Third-quarter sales of the COVID-19 vaccine, which Pfizer sells with BioNTech , came in at $4.40 billion, blowing past estimates of $2.60 billion, according to five analysts polled by Refinitiv. However, Paxlovid, the company's pill to reduce the risk of severe COVID-19, brought in sales of $7.51 billion, missing estimates of $7.66 billion.

☆ What Cramer is watching Tuesday — big J&J deal, Lilly guidance light, Biden scolds Big Oil
▼ + stars: | 2022-11-01 | by ( Jim Cramer | ) www.cnbc.com time to read: +5 min

Club holding J ohnson & Johnson (JNJ) buys Abiomed (ABMD), premier heart pumping company, in a deal valued at $16.6 billion. J & J is paying a hefty premium: $380-per-share upfront, plus extra $35-per-share if certain milestones are met. J & J juiced growth ahead of its separation into two companies: one, pharma and the other, consumer brands. This will raise the growth rate of the MedTech portion of new J & J company. Adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) very good: $516 million versus $470 million expected.

☆ Stocks making the biggest moves in the premarket: Abiomed, Uber, SoFi, Pfizer and more
▼ + stars: | 2022-11-01 | by ( Peter Schacknow | ) www.cnbc.com time to read: +3 min

Uber Technologies (UBER) – Uber rallied 8.8% in the premarket after it reported better-than-expected quarterly revenue as gross bookings surged compared to a year ago. SoFi Technologies (SOFI) – SoFi surged 14.3% in premarket trading, following a smaller-than-expected quarterly loss and revenue that exceeded analysts' forecasts. Pfizer (PFE) – Pfizer jumped 4% in premarket trading following a better-than-expected quarter and an improved financial outlook. Avis Budget (CAR) – Avis Budget shares gained 3.7% in the premarket following better-than-expected quarterly earnings from the rental car giant amid continued strong travel demand. Trex (TREX) – Trex shares tumbled 7.5% in premarket trading after the maker of decking and railing materials missed both top and bottom line estimates for its latest quarter.

☆ Earnings Exchange: NXPI, UBER & PFE
▼ + stars: | 2022-10-31 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailEarnings Exchange: NXPI, UBER & PFEJeff Kilburg, KKM Financial CEO, joins ‘The Exchange’ to discuss three stocks ahead of earnings: NXP Semiconductors, Uber and Pfizer.

Search resuls for: "PFE"

25 mentions found